On Monday, October 24, there will be a meeting of the Transparency Council.
The agenda is:
Preparation of an opinion on the introduction of a comprehensive change to the current description of a drug program B.54. "Treatment of Multiple Myeloma Patients (ICD-10: C90.0)."
Introductory discussion of the problem of drug programs merging:
• the problem of expanding the population,
• adding new drugs without assessing effectiveness and budgetary impact.